KidneyFish
LATINART
Preface
1
Introduction
1.1
Types of study
1.2
Other lists of ‘landmark’ trials
1.3
Going deeper
1.4
Recent trials: see Twitter feed
I AKI
2
AKI
2.1
AKI trials in other chapters
2.2
Association of AKI with mortality & morbidity
2.3
Other trials in AKI
3
Contrast-associated nephropathy
4
Hepatorenal syndrome
4.1
HAS and vasopressors
4.2
Volume status in cirrhosis
II CKD
5
CKD, eGFR, proteinuria
5.1
eGFR
5.2
Association of eGFR and proteinuria with hard outcomes
5.3
Estimating risk of CKD progression
5.4
Competing risk of death
6
Slowing CKD progression
6.1
Lifestyle measures
6.2
Does blood pressure reduction delay
progression of kidney disease
?
6.3
RASi & progression in non-diabetic disease
6.3.1
Starting RASi
6.3.2
Stopping RASi
6.4
SGLT2i
7
Diabetic kidney disease
7.1
Glycaemic control
7.2
RAS blockade
7.3
Dual RAAS blockade
7.4
SGLTi
7.5
GLP1ra
7.6
Four pillars
8
Renal anaemia
8.1
Erythropoetin
8.2
Iron
9
CKD-MBD
9.1
Cinacalcet
9.2
Phosphate binders
III Blood pressure & CVS risk
10
Hypertension in the general population
10.1
Rationale for treating HTN
10.2
Treatment thresholds (in general population)
10.3
Mode of intervention
10.4
Special populations
10.5
Renal dennervation
11
CVS risk in the general population
11.1
Assessing risk
11.2
Interventions to reduce risk
12
CVS risk in CKD
12.1
Statins
12.2
Coronary intervention
12.3
AFib
13
Renovascular disease
IV BODY FLUIDS
14
Fluids, electrolytes & acid-base
14.1
Hyponatraemia
14.2
Hyperkalaemia
14.3
IV fluid therapy
14.4
Diuretic therapy
14.5
Metabolic acidosis
14.5.1
Acidosis of CKD
14.5.2
Renal tubular acidosis
14.5.3
Severe metabolic acidosis
V SPECIFIC KIDNEY DISEASES
15
Glomerular disease
15.1
Proteinuria
15.2
IgAN
15.3
Membranous
15.4
Minimal change
15.5
FSGS
15.6
APOL1 nephropathy
15.7
aHUS
16
ANCA vasculitis
16.1
Induction
16.1.1
Glucocorticoids & Plasma-exchange
16.1.2
Cyclophosphamide
16.1.3
Rituximab
16.1.4
Other agents
16.2
Maintenance
16.3
Adjunctive therapies
17
Lupus nephritis
17.1
Induction
17.2
Maintenance & adjunctive Rx
17.3
Newer therapies
17.3.1
B-cell therapies
17.3.2
CNIs
17.4
Glucocorticoid toxicity
17.5
Contraception
18
ADPKD
18.1
Blood pressure targets and RASi
18.2
Vasopressin antagonist therapy
19
Miscellaneous conditions
19.1
Myeloma
19.2
Pregnancy
19.3
AIN
19.4
Tuberous sclerosis
19.5
Other
VI DIALYSIS
20
Acute dialysis
20.1
Dose
20.2
Timing
21
Chronic dialysis
21.1
Chronic Haemodialysis
21.1.1
Modality
21.1.2
Dose
21.1.3
Initiation
21.2
Peritoneal Dialysis
21.3
Conservative care
VII TRANSPLANT
22
Transplant - donors
22.1
Donor types
22.2
Donor AKI
22.3
Ischaemic time
23
Transplant - immunosuppression & rejection
23.1
Immunosuppression
23.2
Desensitisation
23.3
Rejection
24
Transplant - complications
24.1
CMV disease
24.2
CVS risk
VIII OTHER
25
Historic trials
26
Seminal basic science
27
Other (non-renal) specialties
27.1
Critical care
27.1.1
Sepsis
27.2
Cardiology
27.3
Haematology
Published with bookdown
LATINART
Chapter 25
Historic trials
This chapter is currently being written.